RxDoctor Payments DataLook up a doctor →

Donald Eagerton, MD

Endocrinology, Diabetes & Metabolism · Myrtle Beach, SCNPI 1609872498

Payments from drug & device makers

$7,888,988in general payments, 2019–2025

Across 5,645 payments — averaging $1397.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$5.3M
  • Pfizer$976K
  • Eli Lilly$745K
  • Novo Nordisk AS$314K
  • Boehringer Ingelheim$213K
  • Novo Nordisk$116K
  • plus $223K from 54 others
$2,869in research payments, 2019–2025

Across 3 payments — averaging $956.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.2,668$5,300,344
Pfizer84$976,329
Eli Lilly13$745,369
Novo Nordisk AS1,494$313,802
Boehringer Ingelheim119$213,210
Novo Nordisk172$116,474
Lilly USA, LLC194$66,762
Amgen(2 entities)155$59,205
Sanofi-aventis U.S. LLC76$28,667
Sanofi US Services Inc.14$21,893
Boehringer Ingelheim International GmbH42$16,906
Merck20$9,946
Lexicon Pharmaceuticals, Inc.1$4,802
GSK5$2,231
Medtronic(2 entities)21$1,968
AbbVie(2 entities)68$1,881
Abbott47$1,232
UCB, Inc.65$1,088
Johnson & Johnson(2 entities)80$1,045
AstraZeneca(2 entities)27$935
Radius Health, Inc.38$614
Antares Pharma, Inc.21$341
Dexcom, Inc.22$339
Bayer13$280
Mallinckrodt Hospital Products Inc.16$243
Amarin Pharma, Inc.18$240
Novartis15$227
Xeris Pharmaceuticals, Inc.11$186
Daiichi Sankyo Inc.9$151
Insulet Corporation5$149
Mannkind Corporation8$130
BETA Bionics, Inc.4$125
Shire North American Group Inc12$118
Averitas Pharma Inc.4$117
Astellas Pharma US Inc6$115
Calliditas Therapeutics US Inc.5$110
Ultragenyx Pharmaceutical Inc.6$109
Aurinia Pharma U.S., Inc.5$98
Intuity Medical Inc4$90
Otsuka America Pharmaceutical, Inc.4$82
Ascensia Diabetes Care US Inc.4$81
Takeda Pharmaceuticals U.S.A., Inc.5$75
Ascendis Pharma Endocrinology Inc3$74
Pacira Therapeutics, Inc.3$64
Valeritas, Inc.3$57
Recordati_rare_diseases_inc.2$56
Arbor Pharmaceuticals, Inc.4$53
Kyowa Kirin, Inc.2$53
Rhythm Pharmaceuticals, Inc.2$48
Currax Pharmaceuticals LLC3$38
Corcept Therapeutics2$36
Neurocrine Biosciences, Inc.1$35
Mallinckrodt Enterprises LLC2$32
Organon1$28
GRT US Holding, Inc.1$27
Amneal Pharmaceuticals LLC1$25
Vital Connect, Inc1$23
Medicomp Inc1$23
Boston Scientific1$22
Madrigal Pharmaceuticals1$22

How this compares

$7,888,988 in reported general payments places this provider in the 95th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina →

Medicare billing

Part B allowed, 2024
$3,315,165
Medicare patients
1,841
Services billed
281,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Myrtle Beach

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →